Clinical Trial Update: CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CART-123 in relapsed/refractory acute myeloid leukemia, spanning Phase 1 and Phase 2. Current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CART-123

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: UNKNOWN